Science Writers' Seminar on Childhood Cancers

Extraordinary progress has been made in treating childhood cancers. A child diagnosed with cancer in the 1970s had less than a 50 percent chance of surviving for 5 years; today, 5-year survival rates for all childhood cancers are approaching 80 percent. NCI is sponsoring a Science Writers' Seminar to highlight the latest scientific discoveries in children's cancer and treatment on April 26. Speakers will include Drs. Lee Helman and Alan Wayne of NCI; Dr. Donald Small of Johns Hopkins University; and Kathy Russell, acting executive director of the Children's Inn at NIH. An NCI patient will also speak on the experience of having cancer as a child. The seminar will take place from 11 a.m. to 1:30 p.m. in the multipurpose room of the Children's Inn on the NIH campus in Bethesda, Md. Journalists wishing to register for the press briefing should contact Dorie Hightower or Ann Benner in the NCI Press Office at (301) 496-6641 or at ncipressofficers@mail.nih.gov.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap